Physician profile
Allan B Hatch
NPI 1114919107
$3,615.82
in general payments reported to CMS, 2019-2025
24 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $697 · 2021: $912 · 2022: $584 · 2023: $267 · 2024: $262 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $741.72 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $487.05 | 2019-2024 | |
| Pfizer INC. | $426.11 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $380.02 | 2021-2024 | Verquvo |
| Astellas Pharma US INC | $346.79 | 2019-2021 | |
| Boston Scientific Corporation | $200.37 | 2019-2025 | Cds - Mct/Cem Monitoring, Lux-Dx Insertable Cardiac Monitor |
| Amarin Pharma, INC. | $197.55 | 2019-2022 | |
| Abbott Laboratories | $149.28 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $125.57 | 2021-2023 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.05 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $91.90 | 2020-2023 | Farxiga |
| Amgen INC. | $74.23 | 2019-2025 | Repatha, Repatha |
| Lundbeck LLC | $50.45 | 2019-2020 | |
| Irhythm Technologies, INC. | $41.54 | 2024 | Zio Monitor, Zio Xt Patch |
| Philips North America LLC | $41.29 | 2020-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $34.67 | 2023-2024 | Ozempic, Rybelsus |
| Silk Road Medical, INC. | $23.16 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Abbvie INC. | $21.68 | 2024 | |
| Scpharmaceuticals INC. | $20.59 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $19.85 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $16.22 | 2025 | |
| Bridgebio Pharma, INC. | $13.63 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $13.57 | 2023 | Nexletol |
| Hitachi Healthcare Americas Corp. | $6.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Hatch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.